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Available online 21 May 2009Without intervention, ruptured AAA is fatal and the overall
mortality exceeds 85%. Many patients with ruptured aneu-
rysms die in the community. Half, or more, of those
patients arriving in Accident & Emergency may not reach
the operating theatre alive. Among the patients who reach
the operating theatre (for open surgical repair under
general anaesthesia), only about half will leave hospital
alive. These stark figures have changed little over the last
50 years.1 Moreover, the incidence of both elective and
ruptured AAA continues to increase year on year.2 Routine
treatment has been to direct patients suspected of having
a ruptured aneurysm directly to the operating theatre for
open repair, often without confirmation of diagnosis with
pre-operative CT scan.
More recently endovascular repair has been used in
selected patients. The mortality after endovascular repair
of ruptured aneurysm may be much lower and some have
suggested that this should become the new gold standard
treatment of ruptured aneurysms.3 Also, the in-hospital
and 1-year costs of treating ruptured aneurysms by
endovascular repair may be substantially lower than for
treatment by open repair.4 There has been a spate of
systematic reviews of the published series, to suggest that
operative mortality for endovascular repair lies in the
ranges of 20e30%.5e7 However, the reported series are* The IMPROVE trial applicants Powell JT, Thompson SG,
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doi:10.1016/j.ejvs.2009.04.002biased heavily by patient and publication selection. Most
of the systematic reviews, including the most rigorous
one, which concludes ‘‘we believe that the evidence
summarized here is inadequate to recommend widespread
adoption of strategies that include REVAR (EVAR for
ruptures), and that a large multicenter randomized trial
comparing such a strategy with open repair is needed’’.6
The recent appraisal of endovascular aneurysm repair
(EVAR) by the UK National Institute for Health and Clinical
Excellence (NICE) also concluded that EVAR was not rec-
ommended for patients with ruptured AAA, except in the
context of research.8
Two small trials of endovascular versus open repair for
ruptured AAA are underway the AJAX trial in Amsterdam,
supported by the Dutch Heart Foundation 9 and the ECAR
trial in Paris.10 Patients who are relatively haemodynami-
cally stable undergo CT scan and if they are anatomically
suitable for endovascular repair, are offered random-
isation. Both trials are small: AJAX originally planned to
randomise 80 patients but more recently recruitment has
been extended to 120 patients and ECAR proposes to recruit
160 patients.
The Immediate Management of the Patient with
Rupture: Open Versus Endovascular repair (IMPROVE) trial,
ISRCTN48334791, starting in 2009, has a different design. A
total of 600 patients are to be randomized. The point of
randomisation is the clinical diagnosis of ruptured aneu-
rysm, made in participating hospitals. The patients will be
randomized to undergo either immediate CT scan with
endovascular repair wherever possible or open repair, in
which case a CT scan is optional. Patient entry will be
unselected and include those who are haemodynamically
unstable. The trial is powered to show a difference of 30-
day mortality of 14% between the randomized groups, 44%
for open surgery versus 30% for intention for endovasculard by Elsevier Ltd. All rights reserved.
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patients and health providers, of whether a strategy of
preferential endovascular repair of ruptured AAA, versus
the current practice of open repair, significantly reduces
the 30-day and in-hospital mortality of ruptured AAA.
IMPROVE will be the first large randomized trial to test
the hypothesis that an endovascular strategy is associated
with improved survival of patients with ruptured aneu-
rysms. A previous pilot trial proved the feasibility but failed
to show any survival difference between the two random-
ized groups.11
The care protocols used in the IMPROVE trial, with
permissive hypotension, anatomical guidelines for endovas-
cular repair and preference for avoidance of general
anaesthesia until there is control of the aorta may contribute
to improved survival in both arms of the trial.
The IMPROVE trial addresses a different issue to the
AJAX and ECAR trials and it will answer important questions
that cannot be answered by the other trials, including
whether an endovascular first strategy with a CT scan
introduces unacceptable delays into the patient pathway
with adverse clinical consequences. Such potential disad-
vantages may be balanced by advantages in cross sectional
imaging prior to open repair, and in endovascular adjuncts
(e.g. supracoeliac balloon) to control bleeding prior to
aneurysm repair. Since patients excluded from the trial will
be recorded, we shall be able to comment of the general-
isability of the findings of the IMPROVE trial. The trial also
will address which patients (in terms of Hardman score and
aneurysm morphology) derive most benefit from an endo-
vascular strategy and whether benefit is limited to a small
percentage of patients or to the whole cohort.
The provision and funding of health care varies widely
across Europe. Too often it has been thought that the
results of randomized trials conducted in the tax funded
health system of the UK are not applicable to insurance or
privately funded health care systems. However, with
a carefully designed protocol applicable for use in different
European countries, careful research, on both the effec-
tiveness and the cost-effectiveness of novel interventions,
has the potential to provide evidence for policy-makers in
different settings. The trial is open to other European
centres, with the clinical credentials necessary for partic-
ipation. Details of credentialing and other methodology are
available in a web supplement. Already we have partici-
pation from Ireland and Sweden to make IMPROVE a key
European trial.Acknowledgements
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Supplementary data associated with this article can be
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